Last updated: 2026-10-19 21:45:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Rapport Therapeutics, Inc. (RAPP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $28.59, with a market capitalization of $1.32B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.75 to $52.93. This page covers its latest market performance, valuation, price trends and company information.
$1.32B | |
$27.57 | |
$52.93 | |
$6.43 | |
$27.57 | |
236.47K | |
349.76K | |
-- | |
$52.93 | |
$23.75 | |
-- | |
-- |
Rapport Therapeutics, Inc. (RAPP) is trading at $28.61 in after-hours trading as of 2026-10-19 20:36:00, up 3.77% ($1.04) from the regular-session close of $27.57.
After-hours trading shows how investors are pricing RAPP after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Rapport Therapeutics, Inc. (RAPP) moved from $29.85 to $28.59, representing a decline of 4.22% ($1.26).
The stock traded between $26.93 and $31.39 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 282.05 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.6%
RAPP is currently trading at $28.59, placing it 16.6% of the way from its 52-week low of $23.75 to its 52-week high of $52.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 84 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rapport Therapeutics, Inc. (RAPP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.